Table 1. Clinical and Laboratory Characteristics of Hemodialysis Patients Who Were Positive for (Group 1) and Negative for (Group 2) Hepatitis C Virus RNA.
| All Patients (n = 145) | Group 1 (n = 79) | Group 2 (n = 66) | P value | |
| Age, y, mean ± SD a | 47.4 ± 10.4 | 48.1 ± 10.5 | 46.5 ± 9.8 | 0.3 |
| Sex, No. (%) | 0.4 | |||
| Male | 82 (56.5) | 42 (53.1) | 40 (60.6) | |
| Female | 63 (43.4) | 37 (46.8) | 26 (39.3) | |
| Residence, No. (%) | 0.4 | |||
| Rural | 110 (75.8) | 63 (79.7) | 48 (72.7) | |
| Urban | 35 (24.13) | 16 (20.2) | 18 (27.2) | |
| Schistosoma antibodies, No. (%) | 0.4 | |||
| Positive | 87 (60) | 51 (64.5) | 36 (54.5) | |
| Negative | 58 (40) | 28 (35.4) | 30 (45.4) | |
| Duration of hemodialysis, mo, mean ± SD | 33.5 ± 10.6 | 33.2 ± 11 | 31.7 ± 10.07 | 0.1 |
| Positive history of transfusion, No. (%) | 125 (86.2)/20 (13.7) | 70/79 (88.6) | 55/66 (83.3) | 0.4 |
| AST a , IU/L, mean ± SD | 32.7 ± 4.13 | 32.03 ± 4.28 | 31.12 ± 2.97 | 0.1 |
| ALT a , IU/L, mean ± SD | 28.63 ± 5.36 | 29.81 ± 7.28 | 27.65 ± 3.65 | 0.03 |
| Albumin, g/dL, mean ± SD | 3.4 ± 0.5 | 3.42 ± 0.4 | 3.45 ± 0.5 | 0.4 |
| Bilirubin, mean ± SD | 1.9 ± 0.7 | 1.83 ± 0.6 | 1.8 ± 0.5 | 0.1 |
a Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; SD, standard deviation